

An Overview of Natural and Synthetic Coumarin Derivatives as Potential Antidiabetic Agents

Ansari Asif Husain^{1*}, Ansari Sajjad Husain², Nandkishor Dinkarrao Gawhale³, Sharuk L. Khan⁴, Dhamak Vikrant Murlidhar⁵, Falak A. Siddiqui⁴, A. A. Kazi⁴

¹Department of Pharmacognosy, Gangamai College of Pharmacy, Nagaon, Dhule 424001, Maharashtra, India;

²Department of Quality Assurance, Gangamai College of Pharmacy, Nagaon, Dhule 424001, Maharashtra, India;

³Department of Pharmaceutical Chemistry, G. S. Tompe Arts, Commerce and Science College, Chandur Bazar, Amravati 444704, Maharashtra, India;

⁴Department of Pharmaceutical Chemistry, N.B.S. Institute of Pharmacy, AUSA 413520, Maharashtra, India;

⁵Department of Pharmaceutical Chemistry, Dr. Vitthalrao Vikhe Patil Foundations College of Pharmacy, Vilat Ghat, Ahmednagar 414111, Maharashtra, India

*Corresponding Author: -Ansari Asif Husain

Department of Pharmacognosy, Gangamai College of Pharmacy, Nagaon, Dhule 424001, Maharashtra, India Email: asif.rx784@gmail.com.

Doi: 10.47750/pnr.2022.13. S05.114

Abstract

The common term for cis-o-hydroxy cinnamic acid lactones, which all possess the fundamental structure of the benzo a-pyrone mother nucleus, is coumarins. Especially in *Umbelliferae*, *Rutaceae*, *Daphne*, and *Oleaceae*, coumarins are extensively dispersed in the roots, stems, leaves, flowers, fruits, and seeds of higher plants. A few coumarins are also detected in certain microbes and mammals. Certain coumarin molecules may also be synthesized artificially. We have discussed the probable mechanisms behind coumarins' anti-diabetic benefits. Numerous *in vivo* and *in vitro* studies show that coumarins may treat diabetes by reducing inflammation and oxidative stress, enhancing pancreatic function, and reversing aberrant insulin signaling. As a result, they are useful and need further study and development. In conclusion, it is clear that coumarins have a range of biochemical and pharmacological characteristics, some of which have potential therapeutic value that may be useful against diabetes and its consequences. To sum up, improvements in the area have allowed for the isolation or chemical design of novel advantageous compounds with coumarin cores as candidates against diabetes and its consequences; nevertheless, additional study is necessary before safe and effective coumarin medications are employed in the clinic.

Keywords: Coumarin; Diabetes mellitus; DPP-IV; Umbelliferone; Fraxetin

1. INTRODUCTION

Coumarins and their derivatives have received a lot of attention over the years because of their broad range of biological capabilities, including antibacterial, antiviral, anticancer, antioxidant, anti-inflammatory, anti-tuberculosis, anti-influenza, anti-Alzheimer, and anti-hyperlipidemia qualities. These lactones are known as Coumarins because they are all made of the same fundamental skeleton: benzo-a-pyrone mother nucleus. There are several coumarins in higher plants, notably in the *Umbelliferae*, *Rutaceae*, *Daphne*, and *Oleaceae*, as well as microbes and animals, although the majority of them are found in plants. Additionally, some of the coumarin molecules may be synthesized in a lab[1,2].

2. REVIEW OF COUMARIN DERIVATIVES AS ANTIDIABETIC AGENTS

There have been hypotheses about the ability of natural items to cure sickness since antiquity. *Aegle marmelos* Corr., a member of the *Rutaceae* family, is frequently used in Indian Ayurvedic medicine to treat diabetes[3,4]. At a dosage of 250 mg/kg, *Aegle marmelos* fruit extract had a greater impact than Glibenclamide[5]. Traditional Chinese medicine suggested *Umbelliferae* and *Oleaceae* to treat Xiaoke lesion, or diabetes, by coincidence. For the regulation of Treg differentiation, shift towards Th2 and suppression of lymphocyte proliferation in NOD mice, coumarins from *Urtica dentata* inhibited TLR4 signalling pathways and maintained dendritic cells in the immature tolerogenic state, according to Wang et al. This suggests that coumarins could treat T1D[6]. Many active components have been isolated and purified as a result of advances in extraction and separation technologies(**Structure 1**).

Peucedanol glycoside, an extract from *Peucedanum japonicum*, inhibits postprandial hyperglycemia by 39 percent in an oral glucose tolerance test[7]. *Hintonia standleyana*'s ingredients, one of which was confirmed to be 5-O-[beta-D-apiofuranosyl-(1→6)-b-D-glucopyranosyl]-7-methoxy-3',4'-dihydroxy-4-phenylcoumarin in streptozocin-induced diabetic rats[8]. It is difficult to determine whether the coumarins component is the active site because of the complexity of the molecules isolated from plant extracts. Using coumarin's simpler cousin, umbelliferone, blood sugar levels may be brought back to normal[9]. High insulin levels were shown in Ramesh's research to be associated with a decrease in blood glucose levels[10]. Coumarins have been shown to have antihyperglycemic properties by all the data.

3. Effects and Mechanisms of Coumarins on Diabetes

Umbelliferone

To make umbelliferone, *Citrus aurantium* is used as the primary source of coumarin extraction and purification[11] and *Aegle marmelos* Correa. In diabetic rats caused by streptozocin (STZ), oral treatment of umbelliferone at dosages of 30 mg/kg reduced fasting blood glucose and glycated haemoglobin type A1c (HbA1c)[12,13]. By increasing the creation of SOD, GSH, and catalase, umbelliferone may help cells survive oxidative stress (CAT)[14]. Bioactivities of glucopyranoside of umbelliferone were found by Kumar et al.[15]. Using a different approach, Ramesh et al. found that umbelliferone inhibits hydroxyproline levels, reducing the synthesis of misfolded collagen, which might be used to treat diabetic nephropathy and diabetic polyneuropathy caused by collagen[10].

Fraxetin, esculin and esculetin

A traditional Chinese medication known as "cortical faxing" is made up of fraxetin and esculin. Extracted from plants such as *artemisia capillaris* and citrus, Esculetin is aglycone of Esculin. In terms of chemical structure, fraxetin, esculin, and esculetin are all quite similar. Thuong et al. found that the phenolic compound fraxetin had both anti-oxidative and antioxidant properties. For example, a modest quantity of fraxetin (1-5 μ M) effectively prevented the oxidation of LDL (low density lipoprotein). But at 30 μ M of fraxetin, it activated antioxidant enzymes by increasing NF-E2-related factor 2 in the nucleus (Nrf2)[16]. The active sites of antioxidation in fraxetin are 7-OH and 8-OH, according to a structural study of the molecule. Intriguingly, 7-OH has a tendency to build an intramolecular hydrogen bond with 8-OH, making dissociation quicker. Because of this, 7-OH has a higher level of activity[17]. Fructose-1, 6-biphosphatase and glucose-6-phosphatase, two rate-limiting enzymes in glucose metabolism, were boosted by esculetin and fraxetin *in vivo* in another investigation on glucose metabolism[18]. Tissue glucose consumption might be improved as a result of this. Insulin sensitization may be linked to the anti-hypoglycemic effects of esculin, according to research from the group of Kang et al. in C₂C₁₂ cells. Caspase-3 levels in the kidneys of diabetic rats were reduced following esculin treatment[19]. Caspase-3 levels in the kidneys of diabetic rats were reduced following esculin treatment. The antioxidative effects of esculetin on tetrachloromethane-induced hepatic fibrosis are in line with observations that fraxetin reduces oxidative damage to the liver and kidney,[20] by increasing the production of SOD, catalase (CAT), glutathione peroxidase (GPx), and glutathione S transferase (GST)[21]. Esculetin and fraxetin may have comparable pharmacological processes, as shown by the aforementioned investigations.

Osthole and its derivatives

Osthole, which can be found in fructus *cnidii* and *angelica pubescence*, dramatically activated PPAR γ and PPAR α in 3T3-L1 adipocytes in a dose-dependent way. This increased the cells' sensitivity to insulin, which in turn made it easier for fat to be synthesized and stored[22]. Chemically, Osthole differs from thiazolidinediones (TZDs). As PPAR γ is activated only partially, it may be a partial rather than a total PPAR γ activator. TZD's negative effects, including as edoema, weight gain, and congestive heart failure, may thus be avoided while treating diabetes with this medication. This may be because the synergistic regulation of PPAR α / γ -mediated target genes involved in the metabolism of sugars and fatty acids in the liver, fat, and skeletal muscle was discovered by Qi et al. in rats with fatty livers and insulin resistance (IR) produced by high-fat diets[23]. In addition to activating AMPK, osthole has a unique feature. C₂C₁₂ and L6 cell glucose absorption and AMPK phosphorylation were increased by osthole, according to Lee et al.[24]. Osthole derivatives, such as NBM-T-BMX-OS01 [25] and N-hydroxycinnamide derivatives [26], have similar effects on AMPK. When it comes to stimulating AMPK, N-hydroxycinnamide derivatives are far more potent than the original compound itself (osthole). Antioxidant and free radical scavenger, Osthole is also. A nuclear factor E2-related factor-2 (Nrf2) signalling pathway was shown to be activated by osthole, which in turn inhibited NF- κ B and COX-2 expression, reducing renal cell death[27]. A transcription factor called Nrf2 has also been shown to increase antioxidant synthesis, including that of GPx, CAT, and SOD, therefore protecting cells from oxidative stress. Because of this, it seems to be a promising treatment for diabetic nephropathy.

Scoparone

The inner shell of chestnuts yields a significant amount of scoparone, a coumarin derivative. Previous studies have shown the immunosuppressive, vascular relaxant and anti-diabetic characteristics of scoparone to be very effective[28]. Nitric oxide (NO), COX-2, prostaglandin E2 (PGE2), and factor-alpha (TNF- α), interleukin-1 β (IL-1 β) levels in RAW 264.7 murine macrophages were also reduced by the treatment[29]. Scoparone, which suppresses the development of 3T3-L1 pre-adipocytes, lowered the level of PPAR γ expression, which is an interesting finding[30]. Because of this property, the effectiveness of scoparone in treating diabetes is diminished. Scoparone, on the other hand, gives the impression that it might be utilised to treat obesity and prevent diabetes that is associated to obesity. *In vivo*, it protected pancreatic β -cells from the cytotoxicity of IL-1 β and IFN- γ [31]. More precisely, scoparone defends β cells by suppressing NF- κ B activation and decreasing NO production through the IL-1 β and IFN- γ pathways.


Aculeate

An ethanolic extract of *Toddalia asiatica*, which has antioxidative and antihyperglycemic properties, is where aculeatin is obtained from[32]. Upregulation of PPAR γ target genes by Aculeatin, downregulation of inflammatory gene expression by *Mcp1*, *Ccl6*, and *Il6*, and an increase in 3T3-L1 adipocyte differentiation and lipolysis are only a few of the effects of this compound. As a result, this chemical may be used to treat lipid problems as well as diabetes[33]. There is little doubt that obesity and type 2 diabetes are exacerbated by chronic inflammation. Infiltration of macrophages, which release

inflammatory proteins including MCP-1 and IL-6, is characteristic of adipose tissue with obesity-associated diabetes. Insulin resistance may be exacerbated by inhibiting IRS phosphorylation, which MCP-1 and IL-6 may do[34].

Other coumarins and their derivatives

In C₂C₁₂ cells, coumestans may increase the expression of AMPK and acetyl-CoA carboxylases (ACCs). However, it is possible to attribute the coumarin fragment's capacity to benzofurans to other chemicals, and this would reduce their activity greatly[35]. Furocoumarins, including psoralen, have been shown to enhance blood glucose levels and glucose tolerance in diabetic rats by Seo et al.[36]. When exposed to high levels of oxygen, oxidative stress activates the stress-related proteins p-AMPK, SOD, and GPx, whereas apoptotic proteins such as JNK and p-p38 are downregulated. Glucose control in diabetic mice was improved by rutamarin, which was shown to inhibit PTP1B and induce GLUT4 translocation in CHO-K1/GLUT4 cells[37]. Furocoumarin derivatives increased glucose absorption and fat production in 3T3-L1 adipocytes[38]. Atul et al. designed and screened a series of furocoumarins based on natural antidiabetic scaffolds including Sanggenone C, Rutamarin[37], and Luvangetin[39], which exhibited promising antidiabetic activity. In sucrose-loaded animals, many new pyranocoumarins (**26Ia**, **26Ic**, **26IIa**, **26IIb**, **26IIc**, **26IIe**, **26IIe**) might likewise reduce blood glucose and inhibit PTP1B. Apart from that, rats with triton-induced dyslipidemia responded well to their antidyslipidemic effects[40]. It has been shown that the pyranocoumarin-rich extract of *Angelica gigas* Nakai (AGN) may activate the IRS-1/PI3K/GLUT4 pathway and boost PPARc expression in 3T3-L1 cell lines[41] and pyranocoumarins separated from *Clausena harmandiana* stimulated glucose uptake in L6 myotubes[42]. Anomaline (**27**), a pyranocoumarin derivative, boosted HO-1 and Nrf2 mRNA expression and reduced alterations in mitochondrial membrane potential in terms of antioxidation and anti-inflammation. This was accomplished by decreasing the levels of TNF-a, IL-6, and IL-1b, which were also decreased by Anomalin's ability to adversely regulate iNOS and Cox-2[43]. Coumarins such as pyranocoumarins, bi- and tri-coumarins, as well as the more complex ones, may all block alpha-glucosidase. **Structure 1** depicts the structures of all of the coumarins mentioned above.




Structure 1. Structures of Coumarins reported as antidiabetic agents

4. REVIEW OF COUMARIN DERIVATIVES AS DPP-IV INHIBITORS

Antioxidant properties of quercetin and coumarin were studied by **Anand Krishna Singh** et al. The IC_{50} values of diprotin A, quercetin, coumarin, and sitagliptin were determined to be 0.653, 4.02, 54.83, and 5.49 nmol/mL, respectively, in the DPP-IV inhibition tests, respectively. The drug-likeness and docking efficiency of quercetin and coumarin to the DPP-IV protein, as well as their *ex vivo* anti-peroxidative potential, were studied *in silico* as was their anti-peroxidative potential. Quercetin's DPP-IV inhibitory capability was found to be somewhat greater than that of sitagliptin in this investigation. Virtual docking indicated that quercetin and DPP-IV protein form a strong bond. *In vitro* and *ex vivo*, quercetin and coumarin lowered oxidative stress. Both compounds were shown to inhibit DPP-IV and had antioxidant action for the first time, making them potential functional dietary additives for diabetes prevention[44].

Rina Soni and **Shubhangi S. Soman** have found that the 7-amino-3-methylcoumarin derivative, compound 28 (**Structure 2**), might be a potential inhibitor of the DPP-IV pathway. At 25 μ M, one of the drugs showed a 52.90% inhibition of DPP-IV. Chromen-2-one derivatives were shown to be DPP-IV inhibitors in another work by same researchers. As a consequence of the docking investigations, compounds containing aromatic and cyclic secondary amines residue bind in the large and small pockets of DPP-IV enzymes, respectively. A number of coumarin derivatives have been produced and their structures have been studied by researchers. Two of the synthesised compounds exhibited potential DPP-IV inhibitory action at a dose of 10 μ M, despite their lower activity than conventional medicines Vildagliptin and Sitagliptin. Compound 29 (**Structure 2**) was particularly active, inhibiting the enzyme at a concentration of 10 μ M at a rate of 56.8%[45].

This study identified two novel flavonoids from the leaves of *Smilax china* L., bismilachinone and smilachinin. Spectroscopic approaches were used to discover their structures. Compounds were tested at the molecular level for their inhibitory effects on PTP1B, α -glucosidase, and DPP-IV. Compounds 30, 31, and 32 (**Structure 2**) demonstrated moderate DPP-IV inhibitory effects with IC_{50} values of 20.81, 33.12, and 32.93 μ M, respectively.



Structure 2. The Coumarin derivatives reported as DPP-IV inhibitors

5. CONCLUSION

In the fight against diabetes and its consequences, finding medications that are both effective and safe has long been a priority for medical researchers. In light of the fact that type 2 diabetes (T2D) accounts for nearly all cases of the disease, more and more attention is being paid to treatments for T2D that improve insulin resistance, restore beta-cell function, or enhance the incretin system. These include insulin sensitizers and insulin mimetics. Inhibition of SGLT2 has been proposed as a new approach to limit glucose absorption in the renal tubules, hence increasing glucose excretion in the urine and decreasing blood glucose levels.

The anti-diabetic properties of coumarins and the methods by which they work have been examined. Coumarins' antioxidative and anti-inflammatory properties, as well as their effects on pancreatic function and insulin signalling, have all been shown in both *in vivo* and *in vitro* studies. As a result, they are useful and need further investigation and development. A number of biochemical and pharmacological features found in coumarins have been shown to be beneficial in the treatment of diabetes and its complications. In light of the complex pathophysiology of diabetes, the variety of coumarin targets is advantageous for antidiabetic use. In the context of integrative medicine, coumarins might be utilized to treat diabetes and cardiovascular problems or as an auxiliary to other antidiabetic drugs based on evidence-based complementary treatments. The development of novel beneficial compounds with coumarin cores as candidates against diabetes and its consequences has been made possible by breakthroughs in the area, but more study is needed before safe and effective coumarin medications may be utilized in the clinic. It was so determined that certain coumarin compounds could be useful in the treatment of diabetes.

Conflicts of Interests

Declared none

Acknowledgment

None

Ethical Approval

Not applicable

Funding

None

Authorship Contributions

All the authors have contributed equally in this study.

REFERENCES

- [1] Salehian F, Nadri H, Jalili-Baleh L, Youseftabar-Miri L, Abbas Bukhari SN, Foroumadi A, et al. A review: Biologically active 3,4-heterocycle-fused coumarins. *Eur J Med Chem* 2021;212. <https://doi.org/10.1016/j.ejmech.2020.113034>.
- [2] Miao Y, Yang J, Yun Y, Sun J, Wang X. Synthesis and anti-rheumatoid arthritis activities of 3-(4-aminophenyl)-coumarin derivatives. *J Enzyme Inhib Med Chem* 2021;36:450–61. <https://doi.org/10.1080/14756366.2021.1873978>.
- [3] Seema P V., Sudha B, Padayatti PS, Abraham A, Raghu KG, Paulose CS. Kinetic studies of purified malate dehydrogenase in liver of streptozotocin-diabetic rats and the effect of leaf extract of *Aegle marmelose* (L.) Correa ex Roxb. *Indian J Exp Biol* 1996;34:600–2.
- [4] Scott LC. Indigenous Drugs of India. *Am J Trop Med Hyg* 1933;1-13:443–4. <https://doi.org/10.4269/ajtmh.1933.s1-13.443>.
- [5] Kamalakannan N, Prince PSM. Hypoglycaemic effect of water extracts of *Aegle marmelos* fruits in streptozotocin diabetic rats. *J Ethnopharmacol* 2003;87:207–10. [https://doi.org/10.1016/S0378-8741\(03\)00148-X](https://doi.org/10.1016/S0378-8741(03)00148-X).
- [6] Wang J, Lu J, Lan Y, Zhou H, Li W, Xiang M. Total coumarins from *Urtica dentata* Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways. *J Ethnopharmacol* 2013;146:379–92. <https://doi.org/10.1016/j.jep.2013.01.009>.
- [7] Lee SO, Choi SZ, Lee JH, Chung SH, Park SH, Kang HC, et al. Antidiabetic coumarin and cyclitol compounds from *Peucedanum japonicum*. *Arch Pharm Res* 2004;27:1207–10. <https://doi.org/10.1007/BF02975882>.
- [8] Guerrero-Analco JA, Hersch-Martínez P, Pedraza-Chaverri J, Navarrete A, Mata R. Antihyperglycemic effect of constituents from *Hintonia standleyana* in streptozotocin-induced diabetic rats. *Planta Med* 2005;71:1099–105. <https://doi.org/10.1055/s-2005-873137>.
- [9] Ramesh B, Pugalendi K V. Impact of umbelliferone on erythrocyte redox status in STZ-diabetic rats. *Yale J Biol Med* 2005;78:131–8.
- [10] Ramesh B, Pugalendi K V. Effect of umbelliferone on tail tendon collagen and haemostatic function in streptozotocin-diabetic rats. *Basic Clin Pharmacol Toxicol* 2007;101:73–7. <https://doi.org/10.1111/j.1742-7843.2007.00090.x>.
- [11] Wu J, Huang G, Li Y, Li X. Flavonoids from *Aurantii Fructus Immaturus* and *Aurantii Fructus*: Promising phytomedicines for the treatment of liver diseases. *Chinese Med (United Kingdom)* 2020;15. <https://doi.org/10.1186/s13020-020-00371-5>.
- [12] Ramesh B, Viswanathan P, Pugalendi K V. Protective effect of Umbelliferone on membranous fatty acid composition in streptozotocin-induced diabetic rats. *Eur J Pharmacol* 2007;566:231–9. <https://doi.org/10.1016/j.ejphar.2007.03.045>.
- [13] Ramesh B, Pugalendi K V. Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats. *J Med Food* 2006;9:562–6. <https://doi.org/10.1089/jmf.2006.9.562>.
- [14] Ramesh B, Pugalendi K V. Antioxidant role of Umbelliferone in STZ-diabetic rats. *Life Sci* 2006;79:306–10. <https://doi.org/10.1016/j.lfs.2006.01.005>.
- [15] Kumar V, Ahmed D, Anwar F, Ali M, Mujeeb M. Enhanced glycemic control, pancreas protective, antioxidant and hepatoprotective effects by umbelliferone- α -D-glucopyranosyl-(21 \rightarrow 11)- α -D-glucopyranoside in streptozotocin induced diabetic rats. *Springerplus* 2013;2:1–20. <https://doi.org/10.1186/2193-1801-2-639>.
- [16] Thuong PT, Pokharel YR, Lee MY, Kim SK, Bae KH, Su ND, et al. Dual anti-oxidative effects of fraxetin isolated from *Fraxinus rhinophylla*. *Biol Pharm Bull* 2009;32:1527–32. <https://doi.org/10.1248/bpb.32.1527>.
- [17] Medina ME, Itiga C, Álvarez-Idaboy JR. Antioxidant activity of fraxetin and its regeneration in aqueous media. A density functional theory study. *RSC Adv* 2014;4:52920–32. <https://doi.org/10.1039/c4ra08394f>.
- [18] Prabakaran D, Ashokkumar N. Antihyperglycemic effect of esculetin modulated carbohydrate metabolic enzymes activities in streptozotocin induced diabetic rats. *J Funct Foods* 2012;4:776–83. <https://doi.org/10.1016/j.jff.2012.05.005>.
- [19] Kang KS, Lee W, Jung Y, Lee JH, Lee S, Eom DW, et al. Protective effect of esculetin on streptozotocin-induced diabetic renal damage in mice. *J Agric Food Chem* 2014;62:2069–76. <https://doi.org/10.1021/jf403840c>.
- [20] Prabakaran D, Ashokkumar N. Protective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic rats. *Biochimie* 2013;95:366–73. <https://doi.org/10.1016/j.biochi.2012.10.008>.
- [21] Chen X, Ying X, Zhang W, Chen Y, Shi C, Hou Y, et al. The hepatoprotective effect of fraxetin on carbon tetrachloride induced hepatic fibrosis by antioxidative activities in rats. *Int Immunopharmacol* 2013;17:543–7. <https://doi.org/10.1016/j.intimp.2013.08.006>.
- [22] Liang HJ, Suk FM, Wang CK, Hung LF, Liu DZ, Chen NQ, et al. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. *Chem Biol Interact* 2009;181:309–15. <https://doi.org/10.1016/j.cbi.2009.08.003>.
- [23] Qi ZG, Zhao X, Zhong W, Xie ML. Osthole improves glucose and lipid metabolism via modulation of PPAR α / γ -mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats. *Pharm Biol* 2016;54:882–8. <https://doi.org/10.3109/13880209.2015.1089295>.
- [24] Lee WH, Lin RJ, Lin SY, Chen YC, Lin HM, Liang YC. Osthole enhances glucose uptake through activation of AMP-activated protein kinase in skeletal muscle cells. *J Agric Food Chem* 2011;59:12874–81. <https://doi.org/10.1021/jf2036559>.
- [25] Chen TJ, Zhou YF, Ning JJ, Yang T, Ren H, Li Y, et al. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway. *Cell Physiol Biochem* 2015;36:893–906. <https://doi.org/10.1159/000430264>.
- [26] Lee WH, Wu HH, Huang WJ, Li YN, Lin RJ, Lin SY, et al. N-hydroxycinnamide derivatives of osthole ameliorate hyperglycemia through activation of AMPK and p38 MAPK. *Molecules* 2015;20:4516–29. <https://doi.org/10.3390/molecules20034516>.
- [27] Yang SM, Chan YL, Hua KF, Chang JM, Chen HL, Tsai YJ, et al. Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF- κ B-mediated COX-2 expression and apoptosis. *Free Radic Biol Med* 2014;73:260–9. <https://doi.org/10.1016/j.freeradbiomed.2014.05.009>.
- [28] Huang HC, Lee CR, Weng YI, Lee MC, Lee YT. Vasodilator effect of scoparone (6,7-dimethoxycoumarin) from a Chinese herb. *Eur J Pharmacol* 1992;218:123–8. [https://doi.org/10.1016/0014-2999\(92\)90155-W](https://doi.org/10.1016/0014-2999(92)90155-W).
- [29] Seon IJ, Kim YJ, Lee WY, Kyung CK, Seung HB, Gyu BK, et al. Scoparone from *Artemisia capillaris* inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon- γ plus LPS. *Arch Pharm Res* 2005;28:203–8. <https://doi.org/10.1007/BF02977716>.
- [30] Noh JR, Kim YH, Hwang JH, Gang GT, Yeo SH, Kim KS, et al. Scoparone inhibits adipocyte differentiation through down-regulation of peroxisome proliferators-activated receptor γ in 3T3-L1 preadipocytes. *Food Chem* 2013;141:723–30. <https://doi.org/10.1016/j.foodchem.2013.04.036>.
- [31] Kim EK, Kwon KB, Lee JH, Park BH, Park JW, Lee HK, et al. Inhibition of cytokine-mediated nitric oxide synthase expression in rat insulinoma

- cells by scoparone. *Biol Pharm Bull* 2007;30:242–6. <https://doi.org/10.1248/bpb.30.242>.
- [32] Stephen Irudayaraj S, Sunil C, Duraipandiyar V, Ignacimuthu S. Antidiabetic and antioxidant activities of *Toddalia asiatica* (L.) Lam. leaves in Streptozotocin induced diabetic rats. *J Ethnopharmacol* 2012;143:515–23. <https://doi.org/10.1016/j.jep.2012.07.006>.
- [33] Watanabe A, Kato T, Ito Y, Yoshida I, Harada T, Mishima T, et al. Aculeatin, a coumarin derived from *Toddalia asiatica* (L.) Lam., enhances differentiation and lipolysis of 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2014;453:787–92. <https://doi.org/10.1016/j.bbrc.2014.10.027>.
- [34] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011;11:85–97. <https://doi.org/10.1038/nri2921>.
- [35] Nguyen PH, Nguyen TNA, Dao TT, Kang HW, Ndinteh DT, Mbafor JT, et al. AMP-activated protein kinase (AMPK) activation by benzofurans and coumestans isolated from *Erythrina abyssinica*. *J Nat Prod* 2010;73:598–602. <https://doi.org/10.1021/np900745g>.
- [36] Seo E, Lee EK, Lee CS, Chun KH, Lee MY, Jun HS. *Psoralea corylifolia* L. seed extract ameliorates streptozotocin-induced diabetes in mice by inhibition of oxidative stress. *Oxid Med Cell Longev* 2014;2014. <https://doi.org/10.1155/2014/897296>.
- [37] Zhang Y, Zhang H, Yao X gang, Shen H, Chen J, Li C, et al. (+)-Rutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice. *PLoS One* 2012;7. <https://doi.org/10.1371/journal.pone.0031811>.
- [38] Nagai H, Tanaka T, Goto T, Kusudo T, Takahashi N, Kawada T. Phenolic compounds from leaves of *Casimiroa edulis* showed adipogenesis activity. *Biosci Biotechnol Biochem* 2014;78:296–300. <https://doi.org/10.1080/09168451.2014.877821>.
- [39] Das A V., Padayatti PS, Paulose CS. Effect of leaf extract of *Aegle marmelose* (L.) Correa ex Roxb. on histological and ultrastructural changes in tissues of streptozotocin induced diabetic rats. *Indian J Exp Biol* 1996;34:341–5.
- [40] Kumar A, Maurya RA, Sharma S, Ahmad P, Singh AB, Bhatia G, et al. Pyranocoumarins: A new class of anti-hyperglycemic and anti-dyslipidemic agents. *Bioorganic Med Chem Lett* 2009;19:6447–51. <https://doi.org/10.1016/j.bmcl.2009.09.031>.
- [41] Y P, L L, F D, G J. The Hot Water Extract of *Angelica Gigas* Nakai Root Promotes Adipogenic Differentiation via Activation of the Insulin Signaling Pathway in 3T3-L1 Cells. *J Physiol Pharmacol Adv* 2015;5:795. <https://doi.org/10.5455/jppa.20151124115420>.
- [42] Noipha K, Thongthoom T, Songsiang U, Boonyarat C, Yenjai C. Carbazoles and coumarins from *Clausena harmandiana* stimulate glucose uptake in L6 myotubes. *Diabetes Res Clin Pract* 2010;90. <https://doi.org/10.1016/j.diabres.2010.09.005>.
- [43] Khan S, Choi RJ, Lee J, Kim YS. Attenuation of neuropathic pain and neuroinflammatory responses by a pyranocoumarin derivative, anomalin in animal and cellular models. *Eur J Pharmacol* 2016;774:95–104. <https://doi.org/10.1016/j.ejphar.2016.02.008>.
- [44] Singh AK, Patel PK, Choudhary K, Joshi J, Yadav D, Jin JO. Quercetin and coumarin inhibit dipeptidyl peptidase-IV and exhibits antioxidant properties: In silico, in vitro, ex vivo. *Biomolecules* 2020;10. <https://doi.org/10.3390/biom10020207>.
- [45] Soni R, Durgapal SD, Soman SS, George JJ. Design, synthesis and anti-diabetic activity of chromen-2-one derivatives. *Arab J Chem* 2019;12:701–8. <https://doi.org/10.1016/j.arabjc.2016.11.011>.